stoxline Quote Chart Rank Option Currency Glossary
  
Monte Rosa Therapeutics, Inc. (GLUE)
5.33  -0.12 (-2.2%)    04-26 16:00
Open: 5.3691
High: 5.495
Volume: 86,169
  
Pre. Close: 5.45
Low: 5.29
Market Cap: 267(M)
Technical analysis
2024-04-26 4:42:21 PM
Short term     
Mid term     
Targets 6-month :  8.66 1-year :  10.32
Resists First :  7.41 Second :  8.84
Pivot price 6.29
Supports First :  5.11 Second :  4.25
MAs MA(5) :  5.45 MA(20) :  6.46
MA(100) :  5.82 MA(250) :  5.67
MACD MACD :  -0.4 Signal :  -0.2
%K %D K(14,3) :  6.6 D(3) :  4.3
RSI RSI(14): 35.5
52-week High :  8.84 Low :  2.44
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ GLUE ] has closed above bottom band by 21.2%. Bollinger Bands are 52.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.5 - 5.55 5.55 - 5.58
Low: 5.2 - 5.25 5.25 - 5.28
Close: 5.27 - 5.34 5.34 - 5.39
Company Description

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Headline News

Tue, 23 Apr 2024
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference - The Globe and Mail

Tue, 23 Apr 2024
Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results ... - The Globe and Mail

Tue, 16 Apr 2024
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 8.9% - MarketBeat

Wed, 10 Apr 2024
Recent Price Trend in Monte Rosa Therapeutics (GLUE) is Your Friend, Here's Why - Yahoo Finance

Wed, 20 Mar 2024
Companies Like Monte Rosa Therapeutics (NASDAQ:GLUE) Are In A Position To Invest In Growth - Simply Wall St

Fri, 15 Mar 2024
Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth? - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 50 (M)
Shares Float 24 (M)
Held by Insiders 0.8 (%)
Held by Institutions 98.5 (%)
Shares Short 1,680 (K)
Shares Short P.Month 1,840 (K)
Stock Financials
EPS -2.64
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 3.57
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -27.8 %
Return on Equity (ttm) -60.1 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.74
Qtrly Earnings Growth 0 %
Operating Cash Flow -44 (M)
Levered Free Cash Flow -55 (M)
Stock Valuations
PE Ratio -2.03
PEG Ratio 0
Price to Book value 1.48
Price to Sales 0
Price to Cash Flow -6.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android